An algorithm has been proposed for the detection of white coat hypertension among subjects with elevated blood pressure (BP) on at least three clinic visits using home BP monitoring (screening test) and, if this is low, ambulatory BP monitoring (diagnostic test). This study aims to test this strategy in practice. The proposed algorithm was applied in 133 untreated subjects with elevated BP assessed in a previous prospective study using repeated clinic, home and ambulatory BP measurements. The proportions of detected and missed cases of white coat hypertension and the diagnostic value of the algorithm were calculated. By applying the algorithm, 99 subjects (74%) were found eligible for home measurements and 35 (26%) for ambulatory monitoring. There were 38 subjects with white coat hypertension (38%), of whom 15 (39%) were not detected by the proposed strategy. The sensitivity, specificity, and the positive and negative predictive value of the algorithm to diagnose white coat hypertension were 61, 81, 66 and 77%, respectively. Of the 34 subjects with normal BP on the third clinic visit, 15 (42%) had elevated home and/or ambulatory BP. These data suggest that, using the proposed strategy, many white coat hypertensives may remain undetected and may receive unnecessary long-term drug treatment. Therefore, more research is needed on the optimal strategy for detecting white coat hypertension in clinical practice.
Introduction
Several official bodies suggest that in white coat hypertension, physicians may decide to withhold antihypertensive drug treatment, because of the evidence showing the risk of these subjects to be low and close to that of normotensives. [1] [2] [3] [4] Therefore, a strategy is needed for the detection of white coat hypertension in clinical practice.
In 1990, Thomas Pickering 5 first proposed an algorithm for the diagnosis of white coat hypertension using ambulatory and home blood pressure (BP) monitoring. According to this strategy, subjects with persistently elevated clinic BP and no evidence of target organ damage are assessed using home BP monitoring (screening test) and, if this gives normal values, ambulatory monitoring is performed (diagnostic test). 5 This strategy has been endorsed by an ad hoc panel of the American Society of Hypertension, 4 the First International Consensus Conference for Self-Blood Pressure Monitoring 6 and by several other investigators. [7] [8] [9] Recently, the US Centers for Medicare and Medicaid Services (CMS) announced a decision to cover ambulatory BP monitoring for suspected white coat hypertension defined as subjects with elevated clinic but normal home BP and no target organ damage. 10 However, to date, none of the official national guidelines for hypertension management 1-3,11 has adopted such an approach. This is probably because, although there is a lot of evidence about the significance and the usefulness of ambulatory BP in hypertension, 12 with regard to home BP, only few data are available. 6, 12 More importantly, there is no formal study designed to test the usefulness of home BP as a screening test for the diagnosis of white coat hypertension. This study aims to assess the diagnostic value of the proposed strategy for the diagnosis of white coat hypertension in practice.
Subjects and methods
The present analysis is based on data from a previous prospective study designed to compare the diagnosis of hypertension based on clinic vs home vs ambulatory BP. A complete report with the findings of this study has been published. 7 In brief, untreated subjects with diastolic clinic BP 90-115 mmHg and no evidence of target organ damage were assessed using BP measurement on five clinic visits at 3-week intervals over 3 months (triplicate sitting measurements taken by physicians using standard mercury sphygmomanometers). Home BP was measured on six work days within 2 weeks, between the initial and the second clinic visits (duplicate morning and evening measurements using validated electronic devices Omron HEM-705CP) and 24-h ambulatory BP was measured twice, before and after the home BP monitoring period (SpaceLabs 90207 devices).
Subjects with complete clinic, home and ambulatory BP data were included in the analysis. The criteria of the US CMS decision for national insurance coverage of ambulatory monitoring were used for the diagnosis of white coat hypertension. 10 According to these criteria, the average of the first two BP readings of the third clinic visit, average home BP of monitoring days 2-6 and average 24-h ambulatory BP of the initial recording were used for the detection of patients with elevated BP in the clinic, at home and with ambulatory monitoring, respectively. 10 The thresholds for classification of hypertension were 4140/90 mmHg for clinic and home BP and 4135/85 mmHg for 24-h ambulatory BP, as proposed by the US CMS. 10 Additional analysis was performed using daytime ambulatory BP (based on individual patients' sleeping times) 4140/90 mmHg. 4 The diagnostic value of the proposed strategy for the detection of white coat hypertension using home BP and ambulatory BP measurements was assessed by calculating the sensitivity, the specificity and the positive and negative predictive value (the ambulatory method taken as reference method). The level of agreement between home and ambulatory BP in the detection of white coat hypertension was assessed using the kappa statistic. The optimum cutoff for home BP was investigated using a receiver operating characteristic (ROC) curve.
Results
A total of 142 subjects were included in the study and nine were lost to follow-up. Data from 133 subjects were analysed (mean age was 48.4 7 10.2 (s.d.) years, 73 (55%) men, average BP of the initial clinic visit 149.9 7 16.4/98.8 7 9.0 mmHg). By applying the proposed algorithm for the detection of white coat hypertension, 99 subjects (74%) were classified as having persistently elevated BP on the basis of their third clinic visit and the rest 34 (26%) as normotensives (Figure 1 ). Of the 99 subjects screened using home BP monitoring, 64 (65%) had elevated and 35 (35%) normal home BP. Of the 35 subjects with normal home BP, 12 had elevated ambulatory BP (34%), whereas in the rest 23 (66%), ambulatory BP was normal (diagnosed white coat hypertensives).
The sensitivity, specificity and the positive and negative predictive values of home BP used according to the above-mentioned strategy in the diagnosis of white coat hypertension were 61, 81, 66 and 77%, respectively (61, 83, 71 and 75%, respectively, using daytime instead of 24-h average ambulatory BP). The kappa statistic between home and ambulatory BP in the diagnosis of white coat hypertension was 0.42 (95% CI 0.32-0.52), suggesting moderate to poor agreement. An ROC curve that shows the diagnostic accuracy of different cutoff points of home BP in the diagnosis of white coat hypertension is presented in Figure 2 .
Of the 64 patients with elevated clinic and home BP (those not found eligible for ambulatory monitoring according to the algorithm) 49 (77%) had also elevated ambulatory BP, whereas in the rest 15 (23%), ambulatory was normal (undiagnosed cases of white coat hypertension; Figure 1 ). Thus, in this study, 38 subjects (38%) were classified as white coat hypertensives using the formal definition of elevated clinic BP and normal ambulatory BP, of whom 23 (61%) were detected by the proposed algorithm and 15 (39%) were missed (11% of the total group of 133 subjects). Among subjects with Figure 1 Numbers of normotensives, hypertensives and white coat hypertensives as well as undiagnosed white coat hypertensives classified by applying the proposed algorithm. CBP, clinic blood pressure; HBP, home blood pressure; ABP, ambulatory blood pressure; black arrows and circles show the findings by applying the algorithm and grey arrows and circles show additional assessments not included in the algorithm; circles with dotted filling show subjects with elevated blood pressure and circles with white filling show those with normal pressure.
normal BP on the third clinic visit, five (15%) had elevated home BP, four (12%) had elevated ambulatory BP, five (15%) had both home and ambulatory BP elevated, whereas in the rest 20 (58%) all methods suggested normotension.
Discussion
This analysis provides an opportunity to test the proposed strategy for the detection of the white coat hypertension 4,5 using data from a previous prospective study. 7 More BP data were collected in this study than by applying the proposed strategy, thereby allowing the assessment of potential strengths and limitations of this strategy.
The major finding of this study is that among the 38 subjects who had white coat hypertension according to the formal definition (high clinic and normal ambulatory BP), only 23 (61%) were diagnosed when the proposed strategy was applied, leaving an unacceptably high proportion (39%) of white coat hypertensives undetected. In fact, this represents 11% of the total study participants.
According to the proposed algorithm, home BP measurement is regarded as a prerequisite for the use of ambulatory monitoring (if normal then ambulatory BP monitoring is performed), 4, 5 suggesting that elevated home BP can reliably exclude white coat hypertension. However, although this strategy had been first proposed in 1990 5 and several investigators support its usefulness, 4,7-9 to date no study specifically designed to assess its diagnostic value has been published.
Findings similar to the present analysis with regard to the diagnostic value of home BP in the detection of white coat hypertension have been reported by two published studies that also used clinic, ambulatory and home BP measurements in the same subjects: the THOP study 13 (specificity 89%, sensitivity 68%, negative predictive value 97%, positive predictive value 33%) and the Tecumseh study 14 (specificity 93%, sensitivity 43%). Thus, there is significant agreement among these studies in that home BP has high specificity and high negative predictive value, but low sensitivity and low positive predictive value in the detection of white coat hypertension.
The interpretation of the findings with regard to the diagnostic value of home BP used as a screening test is not clear-cut. It is accepted that in multistage screening, the general idea is that the initial test (screening) is the more sensitive one and the subsequent one more specific. 15 For a screening test, it is important to have high specificity and high negative predictive value, 15 as is the case for home BP. However, it is also important that false-negative results can be prevented at the cost of false-positive ones. 15 Therefore, the major limitation of the proposed algorithm for the diagnosis of white coat hypertension is its unsatisfactory sensitivity (61%) in detecting white coat hypertension. 16 The choice of a cutoff is a critical decision that significantly affects the diagnostic value of a test and depends on the relative costs (financial and other) associated with a false-positive and a false-negative test result. If the cost of a false-negative result is the same as that of a false positive, the best cutoff is the one that lies nearest to the top left corner in the ROC curve ( Figure 2) . 15 With different costs it is hard to decide, and the consequences for the patients and the health-care system should be carefully weighed. In the case of white coat hypertension, it is important to reduce the chance for a false-negative diagnosis in order to prevent unnecessary long-term drug treatment of low-risk white coat hypertensives. Of course, the costs of using home BP monitoring should be balanced against the benefits from the detection of white coat hypertensives.
The thresholds used in this study for the diagnosis of clinic, home and ambulatory hypertension were those proposed in the US CMS decision for national insurance coverage of ambulatory monitoring in suspected white coat hypertension. 10 With regard to 24-h and daytime ambulatory BP, the thresholds used have been proposed by several groups of experts 4, 17 and yielded similar conclusions with regard to the diagnostic value of the proposed strategy. It might be argued that clinic and home BP are more 'comparable' to daytime rather than 24-h ambulatory BP, because the latter includes measurements during sleep. On the other hand, 24-h ambulatory BP might be preferrable, first because it is more reproducible than the daytime average 18 and, second, because it includes nocturnal BP Figure 2 Receiver operating characteristic curve comparing the diagnostic value of several cutoff points of home BP in the diagnosis of white coat hypertension.
measurements that have been shown to provide additional prognostic information. 12 With regard to home BP, the 140/90 mmHg cutoff used in this study has been suggested for use in the initial description of the algorithm. 5 Although this threshold is higher than the one that has been proposed for home BP normalcy, 4, 6 such an approach seems to be justified because the use of a higher threshold for the screening test increases the method's sensitivity, thereby leading to fewer cases of false-negative diagnosis of white coat hypertension. It is clear from Figure 2 that the use of a lower threshold for home BP (eg the recommended 135/85 mmHg threshold 4, 6 ) would lead to significant improvement in the specificity of the diagnosis, and also to an unacceptable reduction of the specificity. However, even on using the 140/90 mmHg threshold for home BP, sensitivity does not exceed 60%, which is still unacceptable for a screening test and, therefore, a higher cutoff might be preferrable. By using a higher cutoff (150/95 mmHg), the sensitivity of the strategy approaches 80% but at the cost of using ambulatory monitoring in 57 instead of 35 subjects (increased use by 63%). Using a 160/100 mmHg cutoff, the sensitivity exceeds 90% but ambulatory monitoring is now required in 80% of subjects, which means doubling of the costs of ambulatory monitoring compared to using the 140/90 mmHg cutoff.
Owing to the absence of outcome data on the significance of the white coat effect assessed using home BP monitoring and the low sensitivity of home BP in detecting 'true' white coat hypertensives (those having low ambulatory BP), it could be argued that ambulatory monitoring might be applied in all patients with persistently elevated BP after three clinic visits and no evidence of target organ damage. Such an approach would definitely increase the costs because, according to the present study, the use of ambulatory BP monitoring will be nearly tripled (applied in 99 instead of 35 subjects). However, savings might also be made, first, from the detection of more white coat hypertensives (15 more subjects, in whom treatment may be withheld, out of the 99 candidates for out-of-clinic BP monitoring in this study) and, second, from the avoidance of the costs of home monitoring (in 99 subjects of the total group of 133 in this study). It should be kept in mind that a few weeks of treatment with an antihypertensive drug might exceed the costs of 24-hour ambulatory BP monitoring. Hidden costs of drug treatment should also be considered, such as adverse effects, cost of tests for their detection, additional clinic visits and patients' inconvenience.
Another interesting issue raised by these data, and also by other reports, is that if we are to accept the ambulatory BP as the reference method (as we do for white coat hypertensives), then subjects with normal clinic but elevated ambulatory BP may be regarded as wrongly diagnosed normotensives (15 (42%) of the 34 subjects with normal BP on the third clinic visit, had elevated home and/or ambulatory BP in this study). There is evidence that subjects with normal clinic, but elevated ambulatory BP, have target organ damage similar to that of subjects with sustained hypertension. 19 Another recent study showed that, in contrast to white coat hypertensives who had few previous cardiovascular complications, in subjects with normal clinic but elevated home BP, previous cardiovascular complications were as common as in patients with uncontrolled hypertension. 20 Thus, more research is needed, because some subjects in whom the initial rise in BP is not evident on subsequent clinic visits may benefit from out-of-clinic monitoring, since it might reveal elevated pressure that seems to be associated with increased risk.
In conclusion, these data suggest that using the proposed strategy, many white coat hypertensives may remain undetected and may receive unnecessary long-term drug treatment. Therefore, more research is needed on the optimal strategy for detecting white coat hypertension in clinical practice.
